¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ascorbic Acid type SC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • chitonic acid
    Űſ»ê
  • cholic acid
    ´ãÁó»ê
  • delta-aminolevulinic acid
    µ¨Å¸¾Æ¹Ì³ë·¹ºÒ¸°»ê
  • deoxycholic acid
    µ¥¿Á½ÃÄÝ»ê
  • deoxyribonucleic acid
    µ¥¿Á½Ã¸®º¸ÇÙ»ê, DNA
  • desoxyribonucleic acid
    µ¥¿Á½Ã¸®º¸ÇÙ»ê, DNA
  • dibasic acid
    ÀÌ¿°±â»ê
  • dicarboxylic acid
    µðÄ«¸£º¹½Ç»ê
  • dilute acid
    ¹±Àº»ê
  • essential amino acid
    Çʼö¾Æ¹Ì³ë»ê
  • essential fatty acid
    ÇʼöÁö¹æ»ê
  • ethylenediamine tetraacetic acid
    ¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • fatty acid
    Áö¹æ»ê
  • fixed acid
    °íÁ¤»ê
  • folic acid
    ¿±»ê, Æú»ê
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • desoxyribonucleic acid
    (¢¡deoxyribonucleic acid) µð¿Á½Ã¸®º¸ÇÙ»ê, µð¿£¿¡ÀÌ
  • dibasic acid
    ÀÌ¿°±â»ê
  • dicarboxylic acid
    µðÄ«¸£º¹½Ç»ê
  • dilute acid
    ¹±Àº»ê
  • essential amino acid
    Çʼö¾Æ¹Ì³ë»ê
  • essential fatty acid
    ÇʼöÁö¹æ»ê
  • ethylenediamine tetraacetic acid
    ¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • fatty acid
    Áö¹æ»ê
  • fibril acid
    ¼¶À¯»ê
  • fixed acid
    °íÁ¤»ê
  • folic acid
    Æú»ê, ¿±»ê
  • formic acid
    Æ÷¸§»ê, °³¹Ì»ê
  • free acid
    À¯¸®»ê
  • free fatty acid
    À¯¸®Áö¹æ»ê
  • fumaric acid
    Ǫ¸¶¸£»ê
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • acetoacetic acid
    ¾Æ¼¼Å侯¼¼Æ®»ê.
  • acetoacetic acid
    ¾Æ¼¼Å侯¼¼Æ®»ê
  • acetylsalicylic acid
    ¾Æ¼¼Æ¿»ì¸®½Ç»ê
  • acid phosphatase
    »êÀλêÈ¿¼Ò
  • acid alcohol
    »ê¼º¾ËÄÚ¿Ã.
  • acid ash diet
    »ê¼º½ÄÀÌ.
  • acid aspiration syndrome
    À§»ê ÈíÀÔ ÁõÈıº
  • acid bath
    »ê¿å(ß«é±).
  • acid burn
    »ê¼º¿Ü»ó, »ê¼ºÈ­»ó.
  • acid burn
    »ê¼ºÈ­»ó
  • acid catalyser
    »êÃ˸Å(ß«õºØÚ).
  • acid challenge test
    »ê Åõ¿©½ÃÇè
  • acid citrate dextrose
    »ê ±¸¿¬»ê¿°Æ÷µµ´ç
  • acid dyspepsia
    ´Ù»ê¼º(Òýß«àõ) ¼ÒÈ­ºÒ·®(Áõ).
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü(¡­û¡).
  • monocytic type
    ´ÜÇÙ±¸Çü(Ó¤ú·Ï¹û¡)
  • monocytic type
    ´ÜÇÙ±¸Çü(?Ì´).
  • muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
  • muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
  • muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
  • mutation, plaque-type
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • on off type
    Á¡¸êÇü(ïÇØþúþ).
  • on type
    Áß½ÉÇü.
  • onion skin type
    ¾çÆÄ²®Áú¸ð¾ç
  • organic reaction type
    ±âÁú¼º ¹ÝÀÀÇü(¡­Úãëëúþ).
  • ovulatory type
    ¹è¶õÇü
  • particle, C-type
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • personality disorder, mixed type
    È¥ÀçÇü(ûèî¤úþ) ÀΰÝÀå¾Ö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • chaulmoogric acid
    Â÷¿ï¹«±×¸£»ê(ß«)
  • chenic acid
    þ»ê(ß«)
  • chenodeoxycholic acid
    Ű³ëµð¿Á½ÃÄݸ° »ê(ß«)
  • p-chloromercuribenzoic acid
    p-Ŭ·Î·Î¸ÓÅ¥¸®º¥Á¶»ê(ß«)
  • choleic acid
    ÄÝ·¹»ê(ß«)
  • cholic acid
    ÄÝ»ê(ß«)
  • chorismic acid
    ÄÚ¸®½¿»ê(ß«)
  • citric acid
    ½ÃÆ®¸£»ê(ß«)
  • citric acid cycle
    ½ÃÆ®¸£»êȸ·Î(ß«üÞÖØ)
  • concerted acid-base catalysis
    Çùµ¿ »ê¿°±â Ã˸Å(úðÔÒß«ç¤ÐñõºØÚ)
  • conjugate acid-base pair
    ¦ÁöÀº »ê¿°±â½Ö(ß«ç¤Ðñäª)
  • conservative amino acid replacement
    "º¸Á¸¼º(ÜÁðíàõ) ¾Æ¹Ì³ë»ê ´ëÄ¡(ÓÛöÇ), (ÔÒ) conservative substitution"
  • cortoic acid
    ÄÚ¸£Æ¼¼Ö»ê(ß«)
  • cyclic adenylic acid °í¸® ¾Æµ¥´Ñ»ê(ß«)
    "(ÔÒ)(ÔÒ) adenosine-3',5'-cyclic monophosphate,"
  • cysteic acid
    ½Ã½ºÅ×ÀÎ »ê(ß«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
AP accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p...
Asx amino acid that gives aspartic acid after hydrolysis; asymptomatic
ATS Achard-Thiers syndrome; acid test solution; alpha-D-tocopherol acid succinate; American Thoracic Soc...
BA Bachelor of Arts; backache; bacterial agglutination; basilar artery; basion; benzyladenine; best amp...
BAO-MAO basal acid output to maximal acid output [ratio]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
ATD Alzheimer Type Dementia
AD Alzheimer type dementia
A.T.C.C. American Type Culture Collection
AT1 Angiotensin II type 1
AT1-R Angiotensin II type 1 receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acid-fast nonmotile rod
    Ç׻꼺 ºñ¿îµ¿¼º °£±Õ
  • acid-gel application
    °ÖÇü »ê Àû¿ë
  • adenylic acid deaminase
    ¾Æµ¥´Ò»ê Å»¾Æ¹Ì³ë È¿¼Ò
  • aldobionic acid
    ¾Ëµµºñ¿Â»ê
    C11H19O10COOH. ±× ¼ººÐ´çÀÇ Çϳª·Î¼­ ¿ì·Ð»êÀ» ÇÔÀ¯Çϰí ÀÖ´Â ÀÌ´ç·ùÀ̸ç, ¿©·¯ Á¾·ùÀÇ ½Ä¹°¼º °í¹«¿Í ƯÁ¤ÇÑ º´¿øÃ¼ Áß¿¡ Á¸ÀçÇÑ´Ù. Æó·Å±Õ 3ÇüÀÇ Æ¯¼ö ´Ù´ç·ùÀÇ °¡¼öºÐÇØ¿¡ ÀÇÇØ¼­ ¾òÀ» ¼ö ÀÖ´Ù.
  • allokainic acid
    ¾Ë·ÎÄ«ÀÎ »ê
  • alloxyproteic acid
    ¾Ë·Ï½Ã ´Ü¹é»ê
    ¶§¶§·Î ´¢ Áß¿¡ ¹è¼³µÇ´Â À¯È² ÇÔÀ¯ È­ÇÕ¹°.
  • alpha-oxynaphthoic acid
    ¾ËÆÄ-¿Á½Ã³ªÇÁÅä»ê
    °áÁ¤¼ºÀÇ »ê,OHC10H6COOH.°ú°Å¿¡´Â ¹æºÎÁ¦, ¹æÃëÁ¦·Î »ç¿ëµÇ¾ú´Ù.
  • amino acid L-tryptophan
    ¾Æ¹Ì³ë»ê L-Æ®¸³ÅäÆÇ
  • aminoacetic acid
    ¾Æ¹Ì³ë¾Æ¼¼Æ®»ê, ¾Æ¹Ì³ëÃÊ»ê
    ºñÇʼö ¾Æ¹Ì³ë»ê, NH2CH2COOH. ¸¹Àº ´Ü¹éÁúÀÇ ±¸¼º ¼ººÐÀ¸·Î Á¸ÀçÇÑ´Ù. ÇÕ¼ºµÇ°í ÀÖÀ¸¸ç À§ Á¦»êÁ¦¿Í º¸Ãæ½ÄǰÀ¸·Î »ç¿ëµÇ¾îÁø´Ù. ¶ÇÇÑ ¿©·¯ °¡Áö ±ÙÀ°º´ ¹× ¸»ÃÊÇ÷°ü ºÎÀüÁõÀÇ Ä¡·á¿¡µµ »ç¿ëµÈ´Ù.
  • aminobenzoic acid
    ¾Æ¹Ì³ë ¾È½ÄÇâ »ê
    C7H7NO2. ½Ä¹°°ú µ¿¹°Á¶Á÷¿¡ ³Î¸® ºÐÆ÷Çϸç, ºñŸ¹Î B±ºÀÇ ±¸¼º ¼ººÐ¿¡ °ü°èµÈ´Ù. ¼³ÆÄÁ¦ÀÇ Á¤±ÕÀÛ¿ëÀ» ¹«È¿È­½ÃŲ´Ù.
  • arachidonic acid
    ¾Æ¶ó۵·»ê
    1. °íµµÀÇ ºÒÆ÷È­ Çʼö Áö¹æ»ê. CH3
  • arachidonic acid metabolism
    ¾Æ¶ó۵·»ê ´ë»ç¹°Áú
  • aromatic amino acid
    ¹æÇâÁ· ¾Æ¹Ì³ë»ê
  • arormatic amino acid
    ¹æÇâÁ· ¾Æ¹Ì³ë»ê
  • arsenic acid
    ºñ»ê
    HAsO©þ. À̰ÍÀÇ ¿°À» ºñ»ê¿°À̶ó°í ºÎ¸£¸ç ÀǾàǰÀ¸·Î ¾²ÀδÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
nutritional type cerebellar atrophy A restricted type of cerebellar cortical degeneration, affecting particularly the Purkinje cells of the anterior and superior vermis; probably caused by thiamin deficiency; most frequently seen in chronic alcoholics and then called alcoholic cerebellar degeneration.
(05 Mar 2000)
delayed type hypersensitivity <immunology> Hypersensitivity (increased reaction by the body to a foreign substance such as an antigen or allergen) that does not appear until 24 to 48 hours after the body is exposed to the foreign substance.
(09 Oct 1997)
Swiss type agammaglobulinaemia Group of rare congenital disorders characterised by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an x-linked or autosomal recessive defect. About half of the patients with autosomal recessive scid are deficient in the enzyme adenosine deaminase.
(12 Dec 1998)
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
diabetes, type 1 Insulin dependent diabetes or juvenile diabetes.
(12 Dec 1998)
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á